Medicine Sessions
EMBARK Psychedelic Therapy for Depression April 23, 2024 DOI: 10.1093/9780197762622.003.0007 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or practical guide (clinical manual chapter) Peer reviewed |
|---|---|
| Key points | Proposes that the therapist's role in PAT medicine sessions centers on support, responsiveness, and skillful following, with attention to physical safety, boundaries, and mindful presence. Provides specific interventions and language for the six EMBARK domains and guidance for responding to challenging events and placebo concerns. |
Abstract
AbstractChapter 6 focuses on the medicine sessions of psychedelic-assisted therapy (PAT), where the psychedelic medicine is administered. The chapter outlines the therapist’s role in these sessions, emphasizing the importance of support, responsiveness, and skillful following, ensuring the participant’s physical well-being, maintaining appropriate boundaries, and providing mindful, compassionate attention. The chapter also details how to work within the six EMBARK psychedelic therapy domains during the medicine sessions, providing specific suggestions for interventions and explanatory language for a variety of clinical phenomena that may emerge in the session. The chapter further discusses how to respond to common and challenging events that may arise during the psychedelic medicine session, emphasizing the importance of the therapist’s presence and the quality of their attention. The chapter concludes with a note on challenging experiences and advice for researchers on what to do if a participant believes they received a placebo.
Citations in the library
Cites 217
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 212 more in the library